G1 Therapeutics sell goldmanns
Start price
06.03.24
/
0%
€3.20
Target price
06.03.25
-
Performance (%)
99.69%
End price
07.03.25
-
Summary
This prediction is currently being closed. The SELL prediction by goldmanns for G1 Therapeutics is trending in the completely wrong direction and now has a performance of 99.69%. This prediction was marked as speculative and is excluded from goldmanns's performance statistics.G1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | - | - | - |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by goldmanns for this prediction
In the thread G1 Therapeutics diskutieren
Sell G1 Therapeutics
In the thread Trading G1 Therapeutics
Die von goldmanns gewählte maximale Laufzeit wurde überschritten